oxMIF: we discovered it, we named it, we are drugging it
OncoOne is dedicated to developing novel therapeutics for patients living with solid tumors and chronic inflammatory diseases. Our founders discovered the disease-related and druggable isoform of one of the most important drivers of innate and adaptive immunity: the macrophage migration inhibitory factor (MIF). The founders identified and named this new target the oxidized macrophage migration inhibitory factor or oxMIF.
MIF, a critical yet previously elusive target
Over 3,000 peer-reviewed papers detail MIF’s importance in driving tumor progression and metastases as well as inflammation. MIF is a central mediator of both innate and adaptive immunity in cancer and immunology indications that has remained elusive to drug targeting.
oxMIF, overcoming previous limitations of targeting MIF
MIF aggregates and goes through a confirmational change to oxMIF at sites of inflammation and in malignant tissue. OncoOne’s therapies specifically target oxMIF, which is only found at the site of disease.
Our therapeutic focus: Immunotherapy for Cancer & Autoimmune Diseases
We are developing oxMIF-targeting therapies for oncology and immunology indications. OncoOne’s initial focus is on treating solid tumors while we advance our second anti-oxMIF mAb to treat patients with chronic inflammatory diseases. All indications in our focus represent significant unmet medical needs.